MetaCap

Soligenix (SNGX) vs Theriva Biologics (TOVX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Theriva Biologics is the larger company by market cap ($5.5 million vs $5.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SNGX-37.74%TOVX-48.72%
+9%-21%-51%
Oct 7, 20261 yearNov 20, 2026
SNGX-39.47%TOVX-44.70%
+3%-22%-47%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SNGX versus TOVX key metrics
MetricSNGXTOVX
Share price$0.2201$0.12
Market cap$5.14M$5.51M
1-day change-8.29%-6.25%
YTD return—-42.86%
1-year return—-45.45%
5-year return—-99.86%
P/E ratio (TTM)—0.10
EPS (TTM)$-0.21$1.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-11.08M$-23.74M
52-week high$1.70$0.49
52-week low$0.21$0.12
Distance from 52-week high-87.05%-75.51%
Analyst consensusnonenone
Avg. price target upside+526.99%+1983.33%
Average volume198.15K2.02M
Shares outstanding23.37M45.89M
Employees1315
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Soligenix

SNGX stock →

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Theriva Biologics

TOVX stock →

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

SNGX vs TOVX FAQ

Which is bigger, Soligenix or Theriva Biologics?

Theriva Biologics (TOVX) is larger, with a market capitalization of $5.51M compared with $5.14M for Soligenix (SNGX).

Are Soligenix and Theriva Biologics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons